by The biomarkers market size is predicted to reach USD 207.46 billion by 2030 and is expected to register a CAGR of 14.1% from 2022 to 2030.
The study provides an analysis of the period 2017-2030, wherein 2022 to 2030 is the forecast period and 2021 is considered as the base year.
The market revenue/volume with the help of widespread quantitative and qualitative insights, and forecasts of the market. This report presents a breakdown of the market into forthcoming and niche segments. Additionally, this research study gauges market revenue growth and its drift in global, regional, and country from 2017 to 2030.
Download a Free Sample Copy of this Report@ https://www.precedenceresearch.com/sample/1182
The global biomarkers market size was valued at USD 63.06 billion in 2021. A biomarker is a biological molecule or gene that is used to evaluate pharmaceutical reactions, biological processes, and pathogenic procedures in an effective and accurate manner. Biomarkers can be found in blood, other than bodily fluids, and tissue and are also known as molecular markers or signature molecules.
Diagnostic markets are becoming increasingly demanding. Traditionally, diagnostic instruments were focused on delivering accurate and consistent results; however, the biomarkers market demand includes early diagnosis with consistent and accurate outcomes. Accurately reporting results in the early stages of diseases, particularly cancer, presents considerable obstacles.
The demand for precise diagnostic techniques is growing as the number of life-threatening and chronic disorders rises. Globally, the number of biomarker suppliers, service providers, and producers is increasing, resulting in tremendous biomarkers market potential opportunities.
Table of Contents
Report Scope of the Biomarkers Market
| Report Highlights | Details |
| Market Size | USD 207.46 Billion by 2030 |
| Growth Rate | CAGR of 14.1% from 2021 to 2030 |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Type, Application, Disease |
Market Dynamics
Drivers
Introduction of artificial intelligence in the market
Since few years, oncologists have used biomarkers more than any other disease. Biomarkers are now being employed in clinical settings to monitor disease status, diagnosis, and therapy success. As a result, the global biomarkers market is expected to develop new technologies in response to the severe circumstances of cancer. As a result, the introduction of artificial intelligence is driving the growth of the biomarkers market during the forecast period.
Restraints
High cost of investments
Due to the variance in biomarker performance in illness diagnosis, validating biomarkers takes a long time. As a result, the validation process takes longer time period and costs more money. Due to different categories of biomarkers tend to have common validation and development process steps, the process and schedule for validating and developing biomarkers in similar across biomarkers categories, with a few exceptions.
Alternate endpoints are the most expensive to validate and develop, particularly in clinical studies, due to the significant clinical validation required. Thus, the high cost of investments is restricting factor for the growth of the biomarkers market.
Opportunities
Rising importance of companion diagnostics
The biomarkers and companion diagnostics have become increasingly important in medical practices, resulting in better diagnosis, monitoring, and treatment in a variety of illness areas. It can be used to find patients who are likely to respond well to certain medications or treatments. These tests are frequently performed in conjunction with a particular medicine. As a result, the rising importance of companion diagnostics is creating lucrative opportunities for the growth of the biomarkers market during the forecast period.
Challenges
Validation of biomarkers
The evidence of the clinical utility and validity of biomarker-based assays is required for their usage in clinical settings. This is critical not just for assisting clinicians in their decision making in the practice of evidence-based medicine, but also for obtaining regulatory clearances and adequate funding for the test.
Collecting the data needed to demonstrate clinical utility and validity, on the other hand, may be time consuming and costly procedure, made much more difficult by the lack of industry standards. Thus, the validation of biomarkers is a huge challenge for the market growth.
Report Highlights
- Based on the type, the safety biomarkers segment dominated the global biomarkers market in 2020 with highest market share, owing to increased awareness about low drug attrition rates, routine health checkups, an increase in the population at high risk of acquiring diseases like cardiovascular diseases, kidney disorders, and cancer.
- Based on the application, the drug discovery and development segment dominated the global biomarkers market in 2020 with highest market share. This is attributed to intensive research and development initiatives for the creation of targeted treatments, the capacity to more accurately forecast drug efficacy, and a quick approval process.
- Based on the disease, the cancer segment dominated the global biomarkers market in 2020 with highest market share. A surge in demand for speedy and reliable diagnostic technologies, an increase in global cancer burden, and unsatisfied need for more targeted, customized therapy targets for cancer patients propel the segment growth.
Read Also: Clinical Trials Market Size to Hit US$ 84.43 Bn by 2030
Regional Snapshot
North America is the largest segment for biomarkers market in terms of region.This is attributed to an increase in diseases rates, increased consumer awareness, and technological advances, and improvements in healthcare infrastructure.
Europe region is the fastest growing region in the biomarkers market. This is due to the existence of well-known research institutes and major market players in the region. The increased collaborations between European universities and biomarkers solutions suppliers can be related to the market’s expansion. The Europe region’s healthcare services are likely to improve as biomarker testing becomes more widely available, boosting the growth of the biomarkers market.
Top Players contending in the Market:
The companies focusing on research and development are expected to lead the global biomarkers market. Leading competitors contending in global biomarkers market are as follows:
- Bio-Rad Laboratories, Inc.
- Qiagen
- Epigenomics AG
- Abbott
- Hoffmann-La Roche Ltd.
- Agilent Technologies, Inc.
- Johnson & Johnson Services, Inc.
- Abbott
- Siemens
- Thermo Fisher Scientific, Inc.
In order to better recognize the current status of biomarkers, and policies adopted by the foremost countries, Precedence Research predicted the future evolution of the biomarkers market. This research study bids qualitative and quantitative insights on biomarkers market and assessment of market size and growth trend for potential market segments.
Major Market Segments Covered:
By Type
- Validation
- Efficacy
- Safety
By Disease
- Neurological Diseases
- Cancer
- Immunological Diseases
- Cardiovascular Diseases
- Others
By Application
- Personalized Medicines
- Drug Discovery & Development
- Diagnostics
- Others
By Geography
-
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- United Kingdom
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of Middle East & Africa
- North America
Key Points Covered in biomarkers market Study:
- Growth of biomarkers in 2022
- Market Estimates and Forecasts (2017-2030)
- Market Share Analysis
- Key Drivers and Restraints Shaping Market Growth
- Segment-wise, Country-wise, and Region-wise Analysis
- Competition Mapping and Benchmarking
- Recommendation on Key Winning Strategies
- COVID-19 Impact on Demand for biomarkers and How to Navigate
- Key Product Innovations and Regulatory Climate
- Consumption Analysis
- Production Analysis
- Market and Management
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Biomarkers Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
Chapter 5. COVID 19 Impact on Biomarkers Market
5.1. Covid-19: Biomarkers Industry Impact
5.2. Biomarkers Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Biomarkers Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Biomarkers Market Players to deal with Covid-19 Pandemic Scenario
Chapter 6. Biomarkers Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Rising incidences of cancer
6.1.1.2. Increasing focus on establishment of biomarker-based diagnostic methods
6.1.2. Market Restraints
6.1.2.1. Stringent regulations
6.1.3. Market Opportunities
6.1.3.1. Rapidly expanding applications of biomarkers in diagnostics
6.1.3.2. Technological advancements
Chapter 7. Global Biomarkers Market: Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Biomarkers Market Revenue by Market Players (2019 -2020)
7.1.1.2. Biomarkers Market Revenue Market Share by Market Players (2019 -2020)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Type Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users
Chapter 8. Global Biomarkers Market, By Type
8.1. Biomarkers Market, by Type, 2019-2030
8.1.1. Validation
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Efficacy
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Safety
8.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Biomarkers Market, By Disease
9.1. Biomarkers Market, by Disease, 2019-2030
9.1.1. Neurological Diseases
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Cancer
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Immunological Diseases
9.1.3.1. Market Revenue and Forecast (2019-2030)
9.1.4. Cardiovascular Diseases
9.1.4.1. Market Revenue and Forecast (2019-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Biomarkers Market, By Application
10.1. Biomarkers Market, by Application, 2019-2030
10.1.1. Personalized Medicines
10.1.1.1. Market Revenue and Forecast (2019-2030)
10.1.2. Drug Discovery & Development
10.1.2.1. Market Revenue and Forecast (2019-2030)
10.1.3. Diagnostics
10.1.3.1. Market Revenue and Forecast (2019-2030)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2019-2030)
Chapter 11. Global Biomarkers Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue Forecast by Type(2019-2030)
11.1.2. Market Revenue Forecast by Disease (2019-2030)
11.1.3. Market Revenue Forecast by Application (2019-2030)
11.1.4. U.S
11.1.4.1. Market Revenue Forecast (2019-2030)
11.1.5. Canada
11.1.5.1. Market Revenue Forecast (2019-2030)
11.2. Europe
11.2.1. Market Revenue Forecast by Type (2019-2030)
11.2.2. Market Revenue Forecast by Disease (2019-2030)
11.2.3. Market Revenue Forecast by Application (2019-2030)
11.2.4. UK
11.2.4.1. Market Revenue Forecast (2019-2030)
11.2.5. Germany
11.2.5.1. Market Revenue Forecast (2019-2030)
11.2.6. France
11.2.6.1. Market Revenue Forecast (2019-2030)
11.2.7. Rest of EU
11.2.7.1. Market Revenue Forecast (2019-2030)
11.3. Asia Pacific (APAC)
11.3.1. Market Revenue Forecast by Type (2019-2030)
11.3.2. Market Revenue Forecast by Disease (2019-2030)
11.3.3. Market Revenue Forecast by Application (2019-2030)
11.3.4. China
11.3.4.1. Market Revenue Forecast (2019-2030)
11.3.5. India
11.3.5.1. Market Revenue Forecast (2019-2030)
11.3.6. Japan
11.3.6.1. Market Revenue Forecast (2019-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue Forecast (2019-2030)
11.4. LATAM
11.4.1. Market Revenue Forecast by Type (2019-2030)
11.4.2. Market Revenue Forecast by Disease (2019-2030)
11.4.3. Market Revenue Forecast by Application (2019-2030)
11.4.4. Brazil
11.4.4.1. Market Revenue Forecast (2019-2030)
11.4.5. Rest of LATAM
11.4.5.1. Market Revenue Forecast (2019-2030)
11.5. Middle East and Africa (MEA)
11.5.1. Market Revenue Forecast by Type (2019-2030)
11.5.2. Market Revenue Forecast by Disease (2019-2030)
11.5.3. Market Revenue Forecast by Application (2019-2030)
11.5.4. GCC
11.5.4.1. Market Revenue Forecast (2019-2030)
11.5.5. North Africa
11.5.5.1. Market Revenue Forecast (2019-2030)
11.5.6. South Africa
11.5.6.1. Market Revenue Forecast (2019-2030)
11.5.7. Rest of MEA
11.5.7.1. Market Revenue Forecast (2019-2030)
Chapter 12. Company Profiles
12.1. Bio-Rad Laboratories, Inc.
12.1.1. Company Overview, Business Information, Regional Presence
12.1.2. Product Portfolio Analysis
12.1.2.1. Product Details, Specification, Disease
12.1.3. Revenue, Price, and Gross Margin (2015-2020)
12.1.4. Recent Developments and Strategies
12.2. Qiagen
12.2.1. Company Overview, Business Information, Regional Presence
12.2.2. Product Portfolio Analysis
12.2.2.1. Product Details, Specification, Disease
12.2.3. Revenue, Price, and Gross Margin (2015-2020)
12.2.4. Recent Developments and Strategies
12.3. Epigenomics AG
12.3.1. Company Overview, Business Information, Regional Presence
12.3.2. Product Portfolio Analysis
12.3.2.1. Product Details, Specification, Disease
12.3.3. Revenue, Price, and Gross Margin (2015-2020)
12.3.4. Recent Developments and Strategies
12.4. Abbott
12.4.1. Company Overview, Business Information, Regional Presence
12.4.2. Product Portfolio Analysis
12.4.2.1. Product Details, Specification, Disease
12.4.3. Revenue, Price, and Gross Margin (2015-2020)
12.4.4. Recent Developments and Strategies
12.5. F. Hoffmann-La Roche Ltd.
12.5.1. Company Overview, Business Information, Regional Presence
12.5.2. Product Portfolio Analysis
12.5.2.1. Product Details, Specification, Disease
12.5.3. Revenue, Price, and Gross Margin (2015-2020)
12.5.4. Recent Developments and Strategies
12.6. Agilent Technologies, Inc.
12.6.1. Company Overview, Business Information, Regional Presence
12.6.2. Product Portfolio Analysis
12.6.2.1. Product Details, Specification, Disease
12.6.3. Revenue, Price, and Gross Margin (2015-2020)
12.6.4. Recent Developments and Strategies
12.7. Johnson & Johnson Services, Inc.
12.7.1. Company Overview, Business Information, Regional Presence
12.7.2. Product Portfolio Analysis
12.7.2.1. Product Details, Specification, Disease
12.7.3. Revenue, Price, and Gross Margin (2015-2020)
12.7.4. Recent Developments and Strategies
12.8. Abbott
12.8.1. Company Overview, Business Information, Regional Presence
12.8.2. Product Portfolio Analysis
12.8.2.1. Product Details, Specification, Disease
12.8.3. Revenue, Price, and Gross Margin (2015-2020)
12.8.4. Recent Developments and Strategies
12.9. Siemens
12.9.1. Company Overview, Business Information, Regional Presence
12.9.2. Product Portfolio Analysis
12.9.2.1. Product Details, Specification, Disease
12.9.3. Revenue, Price, and Gross Margin (2015-2020)
12.9.4. Recent Developments and Strategies
12.10. Thermo Fisher Scientific, Inc.
12.10.1. Company Overview, Business Information, Regional Presence
12.10.2. Product Portfolio Analysis
12.10.2.1. Product Details, Specification, Disease
12.10.3. Revenue, Price, and Gross Margin (2015-2020)
12.10.4. Recent Developments and Strategies
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1182
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
